BC Extra | Jul 9, 2019
Financial News

BioNTech broadens investor base with $325M B round

While BioNTech remains quiet about a timeline for a potential listing, the German biotech has further broadened its investor base with multiple Asia-Pacific firms backing a $325 million series B round as it invests in...
BC Extra | Jun 28, 2019
Preclinical News

June 28 Preclinical Quick Takes: BioNTech targets pancreatitis; plus new targets for HIV and more

Anti-glycan mAb licensed by BioNTech could prevent pancreatitis  A Science study from Cold Spring Harbor Laboratory suggests the glycan CA19.9 (sialyl Lewis A), long known as a biomarker of pancreatic disease, actively drives the progression...
BC Extra | May 8, 2019
Company News

May 8 Company Quick Takes: Takeda selling Shire eye drug to Novartis in $3.4B deal; plus BioNTech, Third Rock’s Thrive and more

Takeda off-loads Xiidra, TachoSil  Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) will sell Xiidra lifitegrast to Novartis AG (NYSE:NVS; SIX:NOVN) for $3.4 billion up front, plus $1.9 billion in milestones. Takeda said divesting the dry eye...
BC Extra | Sep 7, 2018
Financial News

Opko's Frost among those charged in ‘pump-and-dump’ schemes

The SEC filed charges against biotech investor and former Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Chairman Phillip Frost alleging that he participated in “pump-and-dump” schemes involving penny stock companies. Frost, who is chairman and CEO at...
BC Week In Review | Mar 9, 2018
Clinical News

MabVax reports Phase I data for cancer candidate MVT-1075

MabVax Therapeutics Holdings Inc. (NASDAQ:MBVX) reported interim data from three patients with CA19.9-positive malignancies in the first cohort of a Phase I trial showing that MVT-1075 was well tolerated and accumulated on target lesions as...
BC Innovations | Nov 2, 2017
Product R&D

Sweet specificity

Siamab Therapeutics Inc. is gearing up to compete in the small but active space of companies targeting sugar groups that are up-regulated in cancer. So far, its technology has produced a lead therapeutic, a deal...
BioCentury | Jul 7, 2017
Finance

Generalists needed

Following a nearly two-year political overhang on the biotech sector, buysiders believe sentiment once again may be turning positive and starting to catch up with the industry’s positive fundamentals. As evidence, they point to the...
BC Week In Review | Jul 7, 2017
Clinical News

MabVax begins Phase I of MVT-1075 in CA19.9-positive cancers

MabVax Therapeutics Holdings Inc. (NASDAQ:MBVX) began an open-label, U.S. Phase I trial to evaluate escalating doses of MVT-1075 in about 22 patients with relapsed or refractory pancreatic cancer and other CA19.9-positive cancers who have failed...
BC Innovations | Jun 15, 2017
Tools & Techniques

Clearing chemistry

A new study has discovered an in vivo use of click chemistry that can rapidly clear drugs from circulation in case of emergency. Although it raises the possibility of a universal safety switch, its adoption...
BC Week In Review | Jun 9, 2017
Clinical News

MabVax reports Phase Ia data for MVT-5873 in pancreatic cancer

MabVax Therapeutics Holdings Inc. (NASDAQ:MBVX) reported data from 32 evaluable patients with locally advanced or metastatic pancreatic cancer in an open-label, dose-escalation, U.S. Phase Ia trial showing that IV MVT-5873 (5B1 antibody, HuMab-5B1) led to...
Items per page:
1 - 10 of 333
BC Extra | Jul 9, 2019
Financial News

BioNTech broadens investor base with $325M B round

While BioNTech remains quiet about a timeline for a potential listing, the German biotech has further broadened its investor base with multiple Asia-Pacific firms backing a $325 million series B round as it invests in...
BC Extra | Jun 28, 2019
Preclinical News

June 28 Preclinical Quick Takes: BioNTech targets pancreatitis; plus new targets for HIV and more

Anti-glycan mAb licensed by BioNTech could prevent pancreatitis  A Science study from Cold Spring Harbor Laboratory suggests the glycan CA19.9 (sialyl Lewis A), long known as a biomarker of pancreatic disease, actively drives the progression...
BC Extra | May 8, 2019
Company News

May 8 Company Quick Takes: Takeda selling Shire eye drug to Novartis in $3.4B deal; plus BioNTech, Third Rock’s Thrive and more

Takeda off-loads Xiidra, TachoSil  Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) will sell Xiidra lifitegrast to Novartis AG (NYSE:NVS; SIX:NOVN) for $3.4 billion up front, plus $1.9 billion in milestones. Takeda said divesting the dry eye...
BC Extra | Sep 7, 2018
Financial News

Opko's Frost among those charged in ‘pump-and-dump’ schemes

The SEC filed charges against biotech investor and former Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Chairman Phillip Frost alleging that he participated in “pump-and-dump” schemes involving penny stock companies. Frost, who is chairman and CEO at...
BC Week In Review | Mar 9, 2018
Clinical News

MabVax reports Phase I data for cancer candidate MVT-1075

MabVax Therapeutics Holdings Inc. (NASDAQ:MBVX) reported interim data from three patients with CA19.9-positive malignancies in the first cohort of a Phase I trial showing that MVT-1075 was well tolerated and accumulated on target lesions as...
BC Innovations | Nov 2, 2017
Product R&D

Sweet specificity

Siamab Therapeutics Inc. is gearing up to compete in the small but active space of companies targeting sugar groups that are up-regulated in cancer. So far, its technology has produced a lead therapeutic, a deal...
BioCentury | Jul 7, 2017
Finance

Generalists needed

Following a nearly two-year political overhang on the biotech sector, buysiders believe sentiment once again may be turning positive and starting to catch up with the industry’s positive fundamentals. As evidence, they point to the...
BC Week In Review | Jul 7, 2017
Clinical News

MabVax begins Phase I of MVT-1075 in CA19.9-positive cancers

MabVax Therapeutics Holdings Inc. (NASDAQ:MBVX) began an open-label, U.S. Phase I trial to evaluate escalating doses of MVT-1075 in about 22 patients with relapsed or refractory pancreatic cancer and other CA19.9-positive cancers who have failed...
BC Innovations | Jun 15, 2017
Tools & Techniques

Clearing chemistry

A new study has discovered an in vivo use of click chemistry that can rapidly clear drugs from circulation in case of emergency. Although it raises the possibility of a universal safety switch, its adoption...
BC Week In Review | Jun 9, 2017
Clinical News

MabVax reports Phase Ia data for MVT-5873 in pancreatic cancer

MabVax Therapeutics Holdings Inc. (NASDAQ:MBVX) reported data from 32 evaluable patients with locally advanced or metastatic pancreatic cancer in an open-label, dose-escalation, U.S. Phase Ia trial showing that IV MVT-5873 (5B1 antibody, HuMab-5B1) led to...
Items per page:
1 - 10 of 333